Sanxing Guo

机构：First Affiliated Hospital of Zhengzhou University · ORCID：0000-0001-7102-7364

发表论文 43 篇 · 总被引 691 次 · h-index 9

代表论文

• AIFM2 promotes hepatocellular carcinoma metastasis by enhancing mitochondrial biogenesis through activation of SIRT1/PGC-1α signaling (2023 · Oncogenesis · 被引 28)
• Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data (2024 · BMC Cancer · 被引 11)
• Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report (2023 · Frontiers in Medicine · 被引 9)
• Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‑institution experience (2024 · Oncology Letters · 被引 8)
• Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study (2024 · Frontiers in Oncology · 被引 7)
• Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 6)